Phaseline

Companies › Zydus Lifesciences

Zydus Lifesciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Desidustat
PHD inhibitor
EGLN1, EGLN2, EGLN3Phase 4Chronic Kidney Diseases–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05515367DesidustatPhase 4Chronic Kidney DiseasesGenitourinaryJun 2025

From the company's SEC filings

Complete response letters from FDA

Targets

EGLN1 (1) EGLN2 (1) EGLN3 (1)

Companies with the same targets

Astellas

Companies built like this

Fertility Center of Las Vegas Granata Bio Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical Hope Medicine (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.